Cancer Endorsement Maintenance Phase 2  
Breast Measures Workgroup 2  
Thursday, May 10, 2012  
4:00 pm ET

AGENDA

4:00 pm  Welcome and Introductions  
Angela Franklin, JD Senior Director  
Lindsey Tighe, MS, Project Manager  
Adeela Khan, MPH, Project Analyst

4:05 pm  Workgroup Review of Breast Measures  
- 1857: Trastuzumab not administered to patients with AJCC stage I (T1c) – III, human epidermal growth factor receptor 2 (HER2) positive breast cancer (ASCO)  
- 1858: Trastuzumab administered to patients with AJCC stage I (T1c) – III, human epidermal growth factor receptor 2 (HER2) positive breast cancer (ASCO)  
- 1878: Human epidermal growth factor receptor 2 (HER2) testing in breast cancer (ASCO)  
- 1855: Quantitative HER2 evaluation by IHC uses the system recommended by the ASCO/CAP guidelines (ASCO; CAP)  
- 0387: Oncology: Hormonal Therapy for Stage IC Through IIIC, ER/PR Positive Breast Cancer (AMA-PCPI)  
- 0391: Breast Cancer Resection Pathology Reporting- pT category (primary tumor) and pN category (regional lymph nodes) with histologic grade (AMA-PCPI)

5:25 pm  Next Steps

5:30 pm  Adjourn

Please use the following information to access the conference call line:  
Dial-in Number: 1- 888- 523-1227  
Conference ID: 4266189  
Event Title: Cancer SC Phase 2 - Breast Measures Workgroup 2

Please note that the registration link will be activated 15 minutes prior to the meeting.